- October 20, 2017 Spero Therapeutics Initiates Clinical Program For Oral Carbapenem SPR994
- October 10, 2017 Spero Therapeutics Licenses Exclusive Rights to SPR994, a Novel Oral Carbapenem Being Studied for Use in Adults
- October 06, 2017 Spero Therapeutics Files Registration Statement for Proposed Initial Public Offering
- October 03, 2017 Spero Therapeutics Announces Positive Phase 1 Clinical Data From Potentiator Platform
- September 06, 2017 Spero Announces Appointment of Frank Thomas to its Board of Directors and Promotions within Leadership Team
- July 11, 2017 Spero Therapeutics to Participate in Anti-Infectives Panel Discussions at the 2017 Infectious Disease Summit
- May 30, 2017 Spero Therapeutics Presents New Data on Lead Potentiator Candidate SPR741 at ASM Microbe 2017
- May 25, 2017 Spero Therapeutics Acquires Novel Gyrase Inhibitors from Vertex Pharmaceuticals
- May 22, 2017 Spero Therapeutics Appoints Joel Sendek as Chief Financial Officer
- May 04, 2017 Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis
Displaying 31 - 40 of 68 results